- 12 Feb 2019
Recipharm, the contract development and manufacturing organisation (CDMO), has appointed a new director of business management for the USA and Canada, the company said in a press release on Tuesday.
- 11 Feb 2019
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.
- 8 Feb 2019
Basilea Pharmaceutica cahsed $5 million from Pfizer’s milestone payment triggered for selling of the antifungal Cresemba in Europe..
- 7 Feb 2019
Pulmatrix can now begin to test in second phase its anti-fungal drug itraconaole inhaled iSPERSE formulation, to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, after the US FDA approved the company’s Investigational New Drug (IND) Application.
- 7 Feb 2019
Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke, the company said in a statement, through an endothelin (ETB receptor) based mechanism of action, of anti-apoptosis and stimulation of hidden stem cells to repair the damaged brain by formation of new neurons and blood vessels.
- 7 Feb 2019
Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.
- 7 Feb 2019
NanoViricides confirmed in a statement that its CEO, Dr. Irach Taraporewala has resigned effective January 31, 2019, for personal reasons, and will continue as a Consultant to help the company with its regulatory advance as needed. The Board has promoted current President and Board Chairman, Dr. Anil Diwan, to Executive Chairman.
- 29 Jan 2019
Innate Pharma will speed up the development of its anti-KIR3DL2 antibody, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.
My Pharmaceutical
Consequences of microbead: What makes microbeads problematic
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered.
